TRVI
Trevi Therapeutics, Inc.
$19.50
+1.55 (+8.64%)
At close · Jul 7
Market Cap
$2.73B
Shares
141,979,708
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 8-K | 2026-06-04 | 2026-06-03 | |
| 8-K | 2026-05-05 | — | |
| 10-Q | 2026-05-05 | 2026-03-31 | |
| DEF 14A | 2026-04-21 | — | |
| 8-K | 2026-04-17 | 2026-04-16 | |
| Investor Event Transcript | 2026-03-31 | — | |
| 10-K | 2026-03-17 | 2025-12-31 | |
| 8-K | 2026-03-17 | — | |
| 8-K | 2026-03-09 | — | |
| 8-K | 2025-12-05 | 2025-12-01 | |
| 8-K | 2025-11-13 | — | |
| 10-Q | 2025-11-13 | 2025-09-30 | |
| 8-K | 2025-08-20 | 2025-08-14 | |
| 10-Q | 2025-08-07 | 2025-06-30 | |
| 8-K | 2025-08-07 | — | |
| 8-K | 2025-06-17 | 2025-06-11 | |
| 8-K | 2025-06-04 | 2025-06-03 | |
| 8-K | 2025-06-02 | — | |
| 8-K | 2025-06-02 | — | |
| 8-K | 2025-05-08 | — | |
| 10-Q | 2025-05-08 | 2025-03-31 | |
| DEF 14A | 2025-04-29 | — | |
| 10-K | 2025-03-18 | 2024-12-31 | |
| 8-K | 2025-03-18 | — | |
| 8-K | 2025-03-10 | — | |
| 8-K | 2025-01-08 | — | |
| 8-K | 2024-12-16 | 2024-12-15 | |
| 8-K | 2024-12-12 | — | |
| 8-K | 2024-12-03 | — | |
| 8-K | 2024-11-06 | — | |
| 10-Q | 2024-11-06 | 2024-09-30 | |
| 8-K | 2024-10-21 | — | |
| 8-K | 2024-10-04 | 2024-10-03 | |
| 8-K | 2024-10-01 | 2024-09-27 | |
| 10-Q | 2024-08-08 | 2024-06-30 | |
| 8-K | 2024-08-08 | — | |
| 8-K | 2024-06-13 | — | |
| 8-K | 2024-05-07 | — | |
| 10-Q | 2024-05-07 | 2024-03-31 | |
| DEF 14A | 2024-04-26 | 2024-06-13 | |
| 8-K | 2024-03-20 | — | |
| 10-K | 2024-03-20 | 2023-12-31 | |
| 10-Q | 2023-11-09 | 2023-09-30 | |
| 8-K | 2023-11-09 | — | |
| 8-K | 2023-08-10 | — | |
| 10-Q | 2023-08-10 | 2023-06-30 | |
| 8-K | 2023-06-29 | 2023-06-28 | |
| 8-K | 2023-05-11 | — | |
| 10-Q | 2023-05-11 | 2023-03-31 | |
| DEF 14A | 2023-05-01 | 2023-06-28 |
Showing 1–50 of 107 filings